查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2069648

口服 GLP-1 藥物市場：按藥物類型、分子、適應症、患者群體、分銷管道和最終用戶分類—市場規模、行業動態、機會分析和預測（2026-2035 年）

Oral GLP-1 Drugs Market: By Drug Type, Molecule, Indication, Patient Population, Distribution Channel, End User - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 280 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球口服GLP-1藥物市場正經歷快速且持續的成長，反映了糖尿病和肥胖症治療領域的重大典範轉移。預計到2025年，該市場規模將達到約65億美元，儘管仍處於發展初期，但其商業性規模已呈現快速擴張的態勢。推動這一強勁市場規模成長的因素包括：主要醫療保健市場對口服GLP-1療法的接受度不斷提高、代謝性疾病盛行率上升，以及醫生對無需注射的腸促胰素治療方法的信心日益增強。

在2025年至2035年的預測期內，該市場預計將呈現強勁的成長勢頭，到2035年將達到約321億美元。這意味著年複合成長率約為24.8%，顯示它是代謝療法領域成長最快的細分市場之一。這一強勁的成長軌跡得益於製劑技術的不斷進步、越來越多的臨床證據證明了其長期療效，以及口服GLP-1候選藥物監管部門批准數量的增加。

顯著的市場趨勢

目前，快速成長的口服GLP-1藥物市場由少數幾家全球領導企業主導，這些企業正推動著這一高成長治療領域的創新、臨床開發和商業性擴張。諾和諾德憑藉其突破性產品Rybelsus，仍然是口服GLP-1領域無可爭議的先驅和市場領導。 Rybelsus是第一個在全球商業化的口服GLP-1受體促效劑。

憑藉著在代謝性疾病領域的深厚專業知識和強大的下一代療法研發管線，禮來公司已成為口服GLP-1受體激動劑領域的強大競爭力量。該公司策略的關鍵在於奧福格列酮（orfogliprone）。這種新型非胜肽類口服GLP-1受體促效劑無需胜肽結構，代表了藥物設計的重大進展。

阿斯特捷利康透過策略許可和合作，特別是收購和開發AZD5004（原名ECC5004），加強了其在口服GLP-1市場的地位。這項措施體現了Astra Zeneca更廣泛的策略，即透過有針對性的夥伴關係和引入外部創新，拓展其代謝和心血管疾病產品組合。

Viking Therapeutics 正迅速崛起為口服 GLP-1 領域的領先新興企業，其開發的口服製劑 VK2735 備受關注。該公司採用雙標靶策略，專注於 GLP-1 和 GIP 受體通路，使其成為下一代代謝疾病治療領域的創新者。

羅氏也透過策略收購Carmot Therapeutics，迅速擴大了在口服GLP-1市場的佔有率。此次收購使羅氏獲得了一系列前景廣闊的腸促胰素療法產品組合，其中包括口服GLP-1候選藥物。

主要成長要素

全球日益嚴重的肥胖流行是推動口服GLP-1藥物市場成長的主要結構性因素。肥胖已成為世界上最常見的慢性疾病之一，目前影響超過10億成年人。肥胖盛行率的不斷上升，使得人們迫切需要有效、可推廣且長期的治療方案，特別是因為肥胖與第二型糖尿病、心血管疾病和METABOLIC INC.症候群等多種合併症密切相關。隨著醫療保健系統日益面臨肥胖帶來的經濟和臨床負擔，對能夠支持持續體重管理的藥物療法的需求不斷成長，這使得口服GLP-1療法成為備受關注的治療領域。

新機會的趨勢

隨著GLP-1療法在更廣泛人群中的普及，口服GLP-1市場正迎來顯著的成長機會。傳統上，GLP-1受體促效劑的使用常常受到患者對注射劑型的抵抗情緒的限制，這阻礙了部分患者群體接受該療法。儘管注射劑型已展現出顯著的臨床療效，但諸如針頭使用、注射焦慮、治療流程複雜以及生活方式不便等問題，仍然阻礙了許多符合條件的患者開始接受治療。口服GLP-1藥物的問世，透過提供更方便的給藥方式，開始著手解決這些挑戰，從而擴大潛在患者群體，並為市場成長開闢新的途徑。

最佳化障礙

療效和藥物動力學的限制預計仍將是限制全球口服GLP-1市場成長的重大挑戰。儘管與注射療法相比，口服製劑具有更高的便利性和患者接受度，但它們也面臨著固有的生物學和藥學挑戰，這些挑戰可能會影響治療效果。與直接將活性成分輸送到體循環的注射型GLP-1受體促效劑不同，口服療法必須經過複雜的胃腸道環境才能在血液中達到治療濃度。這個過程引入了多種變異因素，可能會影響藥物吸收、療效和整體治療的一致性。

目錄

第1章摘要整理：全球口服GLP-1藥物市場

第2章：調查方法與研究框架

  • 研究目標
  • 產品概述
  • 市場區隔
  • 定性研究
    • 一手和二手資訊
  • 量化研究
    • 一手和二手資訊
  • 主要調查受訪者組成：按地區分類
  • 本研究的前提
  • 市場規模估算
  • 數據三角測量

第3章：全球口服GLP-1藥物市場概覽

  • 產業價值鏈分析
  • 產業展望
    • 全球腸促胰素、代謝療法和抗肥胖藥物產業概覽
    • 研發管線競爭：口服Semaglutide、奧福格列酮和下一代共促效劑
    • 與注射 GLP-1 製劑的比較：取得途徑、定價和報銷趨勢。
  • PESTLE分析
  • 波特五力分析
  • 市場成長及前景
    • 2020-2035年市場收入估算與預測
    • 價格趨勢分析：依藥品類型

第4章：全球口服GLP-1藥物市場分析

  • 競爭對手儀表板
    • 市場集中度
    • 企業市場占有率分析，2025 年
    • 競爭對手分析與基準測試

第5章：全球口服GLP-1藥物市場分析

  • 市場動態和趨勢
    • 成長要素
    • 抑制因子
    • 機會
    • 主要趨勢
  • 市場規模及預測，2020-2035年
    • 依藥物類型
      • 關鍵見解
        • 口服胜肽類GLP-1促效劑
        • 低分子量非胜肽類GLP-1促效劑
    • 按分子
      • 關鍵見解
        • Semaglutide（口服）
        • 橄欖核
        • 達努格里普龍
        • 其他有前景的候選藥物
    • 適應症
      • 關鍵見解
        • 2型糖尿病
        • 肥胖/體重管理
        • 心臟代謝疾病/非酒精性脂肪性肝炎
        • 其他
    • 患者分層
      • 關鍵見解
        • 糖尿病患者
        • 肥胖/超重
        • 心血管風險
    • 透過分銷管道
      • 關鍵見解
        • 醫院和專科藥房
        • 零售藥房
        • 網路藥房
    • 最終用戶
      • 關鍵見解
        • 醫院和診所
        • 居家照護
        • 專業中心
    • 按地區
      • 關鍵見解
        • 北美洲
          • 美國
          • 加拿大
          • 墨西哥
        • 歐洲
          • 西歐
            • 英國
            • 德國
            • 法國
            • 義大利
            • 西班牙
            • 其他西歐國家
          • 東歐
            • 波蘭
            • 俄羅斯
            • 其他東歐國家
        • 亞太地區
          • 中國
          • 印度
          • 日本
          • 澳洲和紐西蘭
          • 韓國
          • ASEAN
          • 其他亞太國家
        • 中東和非洲（MEA）
          • 沙烏地阿拉伯
          • 南非
          • UAE
          • 其他中東和非洲國家
        • 南美洲
          • 阿根廷
          • 巴西
          • 其他南美國家

第6章：北美市場分析

第7章：歐洲市場分析

第8章：亞太市場分析

第9章：中東和非洲市場分析

第10章：南美市場分析

第11章：公司簡介

  • Novo Nordisk
  • Eli Lilly
  • Pfizer
  • Structure Therapeutics
  • Viking Therapeutics
  • AstraZeneca
  • Roche
  • Terns Pharmaceuticals
  • Jiangsu Hengrui
  • Innovent Biologics
  • Gan & Lee
  • Boehringer Ingelheim
  • Zealand Pharma
  • OPKO Health/Entera Bio
  • Amgen

第12章附錄

簡介目錄
Product Code: AA06261830

The global oral GLP-1 drugs market is experiencing rapid and sustained expansion, reflecting a major shift in the treatment paradigm for diabetes and obesity management. In 2025, the market is estimated to be valued at approximately USD 6.5 billion, underscoring its early-stage but fast-scaling commercial footprint. This strong valuation is being driven by increasing adoption of oral GLP-1 therapies across key healthcare markets, rising prevalence of metabolic disorders, and growing physician confidence in non-injectable incretin-based treatments.

Over the forecast period from 2025 to 2035, the market is projected to witness exceptional growth momentum, reaching an estimated value of around USD 32.1 billion by 2035. This represents a compound annual growth rate (CAGR) of approximately 24.8%, highlighting one of the fastest-growing segments within the metabolic therapeutics landscape. The robust growth trajectory is supported by continuous advancements in drug formulation technologies, expanding clinical evidence demonstrating long-term efficacy, and increasing regulatory approvals for oral GLP-1 candidates.

Noteworthy Market Developments

The rapidly expanding oral GLP-1 drugs market is currently shaped and dominated by a small group of leading global pharmaceutical companies that are driving innovation, clinical development, and commercial expansion in this high-growth therapeutic area. Novo Nordisk remains the undisputed pioneer and market leader in the oral GLP-1 segment, primarily through its breakthrough product Rybelsus, the first orally administered GLP-1 receptor agonist to achieve global commercialization.

Eli Lilly and Company has emerged as a formidable competitor in the oral GLP-1 space, leveraging its deep expertise in metabolic diseases and strong pipeline of next-generation therapies. A key focus of its strategy is orforglipron. This novel non-peptide oral GLP-1 receptor agonist represents a major advancement in drug design by eliminating the need for peptide-based structures.

AstraZeneca has strengthened its presence in the oral GLP-1 market through strategic licensing and collaboration initiatives, particularly with the acquisition and development of AZD5004, formerly known as ECC5004. This approach reflects AstraZeneca's broader strategy of expanding its metabolic and cardiovascular portfolio through targeted partnerships and external innovation sourcing.

Viking Therapeutics has quickly emerged as a rising contender in the oral GLP-1 space, gaining attention for its development of VK2735 in oral formulation. The company's dual-target approach, focusing on GLP-1 and GIP receptor pathways, has positioned it as an innovative player in the next generation of metabolic therapies.

Roche has also rapidly expanded its footprint in the oral GLP-1 market through the strategic acquisition of Carmot Therapeutics. This acquisition provided Roche with access to a promising portfolio of incretin-based therapies, including oral GLP-1 candidates.

Core Growth Drivers

The escalating global obesity epidemic is a major structural driver accelerating the growth of the oral GLP-1 drugs market. Obesity has evolved into one of the most widespread chronic health conditions worldwide, with more than one billion adults now affected. This expanding prevalence has created an urgent need for effective, scalable, and long-term treatment solutions, particularly as obesity is strongly associated with comorbidities such as Type 2 diabetes, cardiovascular disease, and metabolic syndrome. As healthcare systems increasingly confront the rising economic and clinical burden of obesity, demand for pharmacological interventions that can support sustained weight management continues to rise, positioning oral GLP-1 therapies as a key area of therapeutic interest.

Emerging Opportunity Trends

The expansion of GLP-1 therapy adoption across broader demographic groups is emerging as a significant growth opportunity for the oral GLP-1 market. Historically, the use of GLP-1 receptor agonists was often limited by patient reluctance toward injectable treatments, which created barriers to adoption among certain population segments. While injectable formulations demonstrated strong clinical efficacy, concerns related to needle use, injection anxiety, treatment complexity, and lifestyle inconvenience discouraged many eligible patients from initiating therapy. The introduction of oral GLP-1 medications has begun to address these challenges by offering a more familiar and convenient mode of administration, thereby expanding the potential patient population and creating new avenues for market growth.

Barriers to Optimization

Efficacy and pharmacokinetic limitations are expected to remain significant challenges that could restrain the growth of the global oral GLP-1 market. Although oral formulations offer greater convenience and improved patient acceptance compared to injectable therapies, they face inherent biological and pharmaceutical hurdles that can affect treatment performance. Unlike injectable GLP-1 receptor agonists, which deliver the active compound directly into the systemic circulation, oral therapies must navigate the complex environment of the gastrointestinal tract before reaching therapeutic concentrations in the bloodstream. This process introduces several variables that can influence drug absorption, efficacy, and overall treatment consistency.

Detailed Market Segmentation

By drug type, oral peptide GLP-1 agonists held the dominant position in the global oral GLP-1 market in 2025, accounting for approximately 63% of total revenue. This substantial market share reflects the strong clinical acceptance and established therapeutic value of peptide-based GLP-1 receptor agonists in the treatment of metabolic disorders, particularly Type 2 diabetes and obesity. As the first class of oral GLP-1 therapies to achieve large-scale commercial success, peptide-based formulations have benefited from extensive physician familiarity, widespread patient adoption, and years of accumulated clinical experience.

By molecule, oral semaglutide emerged as the dominant product category within the oral GLP-1 market, accounting for approximately 52.4% of total molecule-segment revenues in 2025. This commanding market position reflects the molecule's strong clinical profile, widespread physician acceptance, and early establishment as the first commercially successful oral GLP-1 receptor agonist. The introduction of oral semaglutide represented a significant advancement in metabolic disease treatment by providing patients with the benefits of GLP-1 therapy in a convenient oral formulation, thereby addressing a key barrier associated with injectable treatments.

By population, the diabetic patient segment accounted for the largest share of the oral GLP-1 market in 2025, reflecting the substantial and sustained demand generated by individuals requiring long-term diabetes management. The dominance of this population segment is rooted in the chronic nature of diabetes, a condition that typically necessitates lifelong medical treatment, continuous monitoring, and ongoing therapeutic intervention. Unlike short-term treatment categories, diabetes management involves consistent medication use over extended periods, creating a stable and highly predictable demand pattern for pharmaceutical manufacturers.

By disease indication, Type 2 Diabetes represented the largest commercial segment of the oral GLP-1 market, accounting for approximately 62.3% of total revenue in 2025. The segment's dominant position is primarily supported by the growing global burden of Type 2 Diabetes, which continues to affect hundreds of millions of individuals worldwide. As healthcare systems increasingly prioritize effective long-term management of chronic metabolic disorders, oral GLP-1 therapies have emerged as a preferred treatment option due to their ability to improve glycemic control while also delivering additional benefits such as weight reduction and cardiovascular risk mitigation.

Segment Breakdown

By Drug Type

  • Oral Peptide GLP-1 Agonists
  • Small-Molecule Non-Peptide GLP-1 Agonists

By Molecule

  • Semaglutide (Oral)
  • Orforglipron
  • Danuglipron
  • Other Emerging Candidates

By Indication

  • Type 2 Diabetes
  • Obesity / Weight Management
  • Cardiometabolic / NASH
  • Others

By Patient Population

  • Diabetic
  • Obese / Overweight
  • Cardiovascular-Risk

By Distribution Channel

  • Hospital & Specialty Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By End User

  • Hospitals & Clinics
  • Homecare
  • Specialty Centers

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America is expected to maintain its position as the largest contributor to the global oral GLP-1 market in 2026, accounting for approximately 46% to 50% of total market revenue. The region's leadership is primarily attributed to the substantial burden of metabolic disorders, particularly obesity and diabetes, which continue to pose major public health challenges. In the United States, the prevalence of obesity has reached critical levels, with data from the Centers for Disease Control and Prevention indicating that more than 42% of adults are living with obesity.
  • The region's dominance is further reinforced by its highly developed healthcare ecosystem, which supports the rapid introduction and adoption of advanced pharmaceutical products. North America benefits from extensive healthcare infrastructure, robust reimbursement frameworks, and widespread access to specialized medical care. Leading hospitals, diabetes centers, and endocrinology networks are well equipped to integrate newly approved oral GLP-1 therapies into treatment protocols, enabling faster uptake compared with many other regions.

Leading Market Participants

  • Novo Nordisk
  • Eli Lilly
  • Pfizer
  • Structure Therapeutics
  • Viking Therapeutics
  • AstraZeneca
  • Roche
  • Terns Pharmaceuticals
  • Jiangsu Hengrui
  • Innovent Biologics
  • Gan & Lee
  • Boehringer Ingelheim
  • Zealand Pharma
  • OPKO Health / Entera Bio
  • Amgen

Table of Content

Chapter 1. Executive Summary: Global Oral GLP-1 Drugs Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Oral GLP-1 Drugs Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. API & Drug Substance Suppliers (Peptides, Small Molecules, Absorption Enhancers)
    • 3.1.2. Oral GLP-1 Drug Developers & Manufacturers
    • 3.1.3. Formulation & Oral Delivery Technology Providers
    • 3.1.4. Distribution Channels (Hospital, Retail, Online Pharmacies)
    • 3.1.5. Healthcare Providers (Hospitals, Clinics, Specialty Centers) & Patients
  • 3.2. Industry Outlook
    • 3.2.1. Overview of the Global Incretin / Metabolic Therapy & Anti-Obesity Industry
    • 3.2.2. Pipeline Race: Oral Semaglutide, Orforglipron & Next-Gen Co-Agonists
    • 3.2.3. Access, Pricing & Reimbursement Dynamics vs. Injectable GLP-1s
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis, By Drug Type

Chapter 4. Global Oral GLP-1 Drugs Market Analysis

  • 4.1. Competition Dashboard
    • 4.1.1. Market Concentration Rate
    • 4.1.2. Company Market Share Analysis (Value %), 2025
    • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Oral GLP-1 Drugs Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Drug Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Oral Peptide GLP-1 Agonists
        • 5.2.1.1.2. Small-Molecule Non-Peptide GLP-1 Agonists
    • 5.2.2. By Molecule
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Semaglutide (Oral)
        • 5.2.2.1.2. Orforglipron
        • 5.2.2.1.3. Danuglipron
        • 5.2.2.1.4. Other Emerging Candidates
    • 5.2.3. By Indication
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Type 2 Diabetes
        • 5.2.3.1.2. Obesity / Weight Management
        • 5.2.3.1.3. Cardiometabolic / NASH
        • 5.2.3.1.4. Others
    • 5.2.4. By Patient Population
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Diabetic
        • 5.2.4.1.2. Obese / Overweight
        • 5.2.4.1.3. Cardiovascular-Risk
    • 5.2.5. By Distribution Channel
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. Hospital & Specialty Pharmacies
        • 5.2.5.1.2. Retail Pharmacies
        • 5.2.5.1.3. Online Pharmacies
    • 5.2.6. By End User
      • 5.2.6.1. Key Insights
        • 5.2.6.1.1. Hospitals & Clinics
        • 5.2.6.1.2. Homecare
        • 5.2.6.1.3. Specialty Centers
    • 5.2.7. By Region
      • 5.2.7.1. Key Insights
        • 5.2.7.1.1. North America
          • 5.2.7.1.1.1. The U.S.
          • 5.2.7.1.1.2. Canada
          • 5.2.7.1.1.3. Mexico
        • 5.2.7.1.2. Europe
          • 5.2.7.1.2.1. Western Europe
            • 5.2.7.1.2.1.1. The UK
            • 5.2.7.1.2.1.2. Germany
            • 5.2.7.1.2.1.3. France
            • 5.2.7.1.2.1.4. Italy
            • 5.2.7.1.2.1.5. Spain
            • 5.2.7.1.2.1.6. Rest of Western Europe
          • 5.2.7.1.2.2. Eastern Europe
            • 5.2.7.1.2.2.1. Poland
            • 5.2.7.1.2.2.2. Russia
            • 5.2.7.1.2.2.3. Rest of Eastern Europe
        • 5.2.7.1.3. Asia Pacific
          • 5.2.7.1.3.1. China
          • 5.2.7.1.3.2. India
          • 5.2.7.1.3.3. Japan
          • 5.2.7.1.3.4. Australia & New Zealand
          • 5.2.7.1.3.5. South Korea
          • 5.2.7.1.3.6. ASEAN
          • 5.2.7.1.3.7. Rest of Asia Pacific
        • 5.2.7.1.4. Middle East & Africa (MEA)
          • 5.2.7.1.4.1. Saudi Arabia
          • 5.2.7.1.4.2. South Africa
          • 5.2.7.1.4.3. UAE
          • 5.2.7.1.4.4. Rest of MEA
        • 5.2.7.1.5. South America
          • 5.2.7.1.5.1. Argentina
          • 5.2.7.1.5.2. Brazil
          • 5.2.7.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. Key Insights
      • 6.2.1.1. By Drug Type
      • 6.2.1.2. By Molecule
      • 6.2.1.3. By Indication
      • 6.2.1.4. By Patient Population
      • 6.2.1.5. By Distribution Channel
      • 6.2.1.6. By End User
      • 6.2.1.7. By Country

Chapter 7. Europe Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. Key Insights
      • 7.2.1.1. By Drug Type
      • 7.2.1.2. By Molecule
      • 7.2.1.3. By Indication
      • 7.2.1.4. By Patient Population
      • 7.2.1.5. By Distribution Channel
      • 7.2.1.6. By End User
      • 7.2.1.7. By Country

Chapter 8. Asia Pacific Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. Key Insights
      • 8.2.1.1. By Drug Type
      • 8.2.1.2. By Molecule
      • 8.2.1.3. By Indication
      • 8.2.1.4. By Patient Population
      • 8.2.1.5. By Distribution Channel
      • 8.2.1.6. By End User
      • 8.2.1.7. By Country

Chapter 9. Middle East & Africa Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. Key Insights
      • 9.2.1.1. By Drug Type
      • 9.2.1.2. By Molecule
      • 9.2.1.3. By Indication
      • 9.2.1.4. By Patient Population
      • 9.2.1.5. By Distribution Channel
      • 9.2.1.6. By End User
      • 9.2.1.7. By Country

Chapter 10. South America Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. Key Insights
      • 10.2.1.1. By Drug Type
      • 10.2.1.2. By Molecule
      • 10.2.1.3. By Indication
      • 10.2.1.4. By Patient Population
      • 10.2.1.5. By Distribution Channel
      • 10.2.1.6. By End User
      • 10.2.1.7. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. Novo Nordisk
  • 11.2. Eli Lilly
  • 11.3. Pfizer
  • 11.4. Structure Therapeutics
  • 11.5. Viking Therapeutics
  • 11.6. AstraZeneca
  • 11.7. Roche
  • 11.8. Terns Pharmaceuticals
  • 11.9. Jiangsu Hengrui
  • 11.10. Innovent Biologics
  • 11.11. Gan & Lee
  • 11.12. Boehringer Ingelheim
  • 11.13. Zealand Pharma
  • 11.14. OPKO Health / Entera Bio
  • 11.15. Amgen

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators